Comparative evaluation of prednisolone 5MG tablets marketed in Bangladesh by Morshed, Nabila
 
I 
 
COMPARATIVE EVALUATION OF PREDNISOLONE 
5MG TABLETS MARKETED IN BANGLADESH 
 
 
 
A PROJECT SUBMITTED TO THE DEPARTMENT OF PHARMACY,  
BRAC UNIVERSITY 
IN PARTIAL FULFILMENT OF THE REQUIREMENT FOR THE DEGREE OF 
BACHELOR OF PHARMACY  
   
 
SUBMITTED BY: 
NABILA MORSHED 
ID: 11146002 
SESSION: SPRING 2011 
SUBMISSION ON: MARCH 2015 
DEPARTMENT OF PHARMACY  
BRAC UNIVERSITY 
 
 
 
 
 
II 
 
Acknowledgement 
 
I would like to express my thanks and gratitude to the Department of Pharmacy, BRAC 
University for providing me the laboratory facilities for the completion of the project. I am also 
thankful to my supervisor, Ms. Shahana Sharmin for her dedicated supervision and obliged to all 
those who have given me their valuable time and energy from their hectic work schedule to 
express their full experience about the instrumental terms, conditions and working procedures. 
Special thanks to the GlaxoSmithKline (Bd) Ltd. Pharmaceuticals for proving us the working 
standard. 
 
I want to specially acknowledge for the immense support, helpful and creative contributions of 
the following people: 
 Professor Mohammad Shawkat Ali, Chairperson, Department of Pharmacy, BRAC 
University. 
 Ms. Shahana Sharmin, Senior Lecturer, Department of Pharmacy, BRAC University. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III 
 
 
Abstract 
 
The aim of the present study is to determine the quality and to correlate with other different 
brands of pharmaceutical products marketed in Bangladesh for the healthcare of patients 
suffering from different respiratory inflammation like asthma, and auto-immune disorders. The 
experiment is done to evaluate and compare the physicochemical equivalence of different brands 
of Prednisolone 5mg tablet. These tablets were tested through statistical methods in accordance 
with the BP and USP like weight variation, thickness, hardness, friability, disintegration, in-vitro 
dissolution and HPLC assay. The in vitro dissolution studies of Prednisolone 5 mg tablets were 
carried out in pH 7 distilled water for 30 minutes using USP-II method whose absorbance were 
taken at 246 nm using UV spectrophotometry. Six samples showed poor in-vitrodissolution 
whichwere non-equivalent to the USP monograph specification giving Prednisolone content less 
than 75%. The percentage content of active ingredient of different brands were tested using 
HPLC assay. Samples showed values within the specifications (90-110%) except some of the 
companies. Two samples did not undergo disintegration at all when given in the disintegration 
tester. However, no major problem was found in others physical parameters like tablet weight 
variation, thickness, hardness and friability. Finally from the experiment we can conclude that 
50% of the companies in the urban area are substandard, whereas 50% companies provide 
standard drugs. 
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1.1 Introduction 
Medicines need to be safe, effective and of good quality in order to produce the desired effect. 
Ensuring these properties requires the creation of competent national drug regulatory authorities 
with the necessary human and other resources to control the manufacture, importation, 
distribution and sale of medicines. The necessity of any drug delivery system is to provide a 
therapeutic amount of drug to the proper site in the body and then maintain the optimum plasma 
concentration for a definite period of time. The quality of a drug is an important factor which 
ensures the health and wellness of a patient. Substandard quality of drugs increases the mortality 
and morbidity in a country. The objective of this project is to evaluate the quality of drug 
available in Bangladesh market which is being used for patients suffering from respiratory 
disorders and various auto-immune disorders. 
 
1.2 Conventional Dosage forms: 
Tablets are solid dosage forms usually obtained by single or multiple compressions of powders 
or granules. In certain cases tablets may be obtained by molding or extrusion techniques. They 
are uncoated or coated.Tabletscontain one or more active ingredients. They may contain 
excipients such as diluents, binders, disintegrating agents, glidants, lubricants, substances 
capable of modifying the behavior of the dosage forms and the active ingredient in the 
gastrointestinal tract, coloring matter authorized by the appropriate national or regional authority 
and flavoring substances. When such excipients are used it is necessary to ensure that they do not 
adversely affect the stability, dissolution rate, bioavailability, safety or efficacy of the active 
ingredient; there must be no incompatibility between any of the components of the dosage 
form.Tablets are single-dose preparations intended for oral administration. Some are intended to 
be swallowed whole, some after being chewed and some after being crushed, some are intended 
to be dissolved or dispersed in water before being taken and some are intended to be retained in 
the mouth where the active ingredient is liberated. 1 
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1.3 Advantages of conventional dosage forms: 
a. They are unit dose form, and they offer the greatest capabilities of all dosage forms for the 
greatest dose precision and the latest content variability. 
b. their cost is lowest of all dosage forms 
c. They are the lightest and most compact of all oral dosage forms 
d. They are in general the easiest and cheapest to package and ship of all oral dosage forms 
e. Product identification is potentially the simplest and cheapest, requiring no additional 
processing steps when employing an embossed or monogrammed punch face. 
f. They may provide the greatest ease of swallowing with the least tendency for ‘hang-up’ above 
stomach, especially when coated provided that tablet disintegration is not excessively rapid. 
g. they lend themselves to certain special release profile products such as enteric or delayed-
release products. 
h. They are better suited to large scale production than other unit oral forms 
i. They have the best combined properties of chemical, mechanical and microbiologic stability of 
all oral forms. 
 
1.4 Disadvantages of conventional oral dosage forms:  
a. Some drugs resist compression into dense compacts, owing to their amorphous nature or 
flocculent, low-density character. 
b. Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, optimum 
absorption high in the gastrointestinal tract, or any combination of these features may be difficult 
or impossible to formulate and manufacture as a tablet that will still provide adequate or full drug 
bioavailability.  
c. Bitter tasting drugs, drugs with an objectionable odor, or drugs that are sensitive to oxygen or 
atmospheric moisture may require encapsulation or entrapment prior to compression or the 
tablets may require coating.2 
 
1.5 Diseases which are treated with prednisolone: 
Respiratory disorders are an increasing day by day and affecting majority of people due to 
increasing air pollution. Glucocorticoids are commonly used to treat a wide range of respiratory 
inflammatory diseases like asthma. They are thought to decrease the chronic inflammation in the 
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bronchiole tree, thereby improving obstructed airflow. The main API (active pharmaceutical 
ingredient) of this project is prednisolone. Prednisolone is a corticosteroid drug with 
predominant glucocorticoid and low mineralocorticoid activity, making it useful for the 
treatment of a wide range of inflammatory and auto-immune conditions such as asthma. 
Prednisolone can also be used as an immunosuppressive drug for organ transplants and in cases 
of adrenal insufficiency (Addison's disease).3 Prednisolone is a man-made form of a natural 
substance (corticosteroid hormone) made by the adrenal gland. It is used to treat conditions such 
as arthritis, blood problems, immune system disorders, skin and eye conditions, breathing 
problems, cancer, and severe allergies. It decreases immune system's response to various 
diseases to reduce symptoms such as pain, swelling and allergic-type reactions.  
Corticosteroids inhibit the inflammatory response to a variety of inciting agents and, it is 
presumed, delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, 
leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and 
scar formation with inflammation.4Corticosteroids are considered to be one of the most effective 
medicines for asthma by suppressing airway inflammation.12  
The WHO has been tracking and documenting the incidences of substandard drugs. The records 
show that problems of substandard and counterfeit drugs are on increase as 50% of all reported 
cases occurred in the period 1993 to 1997. Most of these incidences (70%) were reported in 
developing countries. The report identifies the causes of the poor quality of drugs: in about 50% 
of all the cases the formulations did not contain any drug, 20% contained the wrong active 
ingredient and 10% the wrong amount of the active ingredient. Only in 5% of the reported 
incidences did the drugs contain the right active ingredient in the correct amounts, but were 
judged substandard by failing other quality tests.5 
9 percent of pharmaceutical sales in Bangladesh have been traced to counterfeit or low-quality 
drugs, openly sold in pharmacies.6 
This project focuses on the evaluation of the prednisolone dosage form and its basic parameters 
which evaluated the drug quality and shows whether they meet the USP requirements as claimed 
by the manufacturing companies. 
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1.6 Drug Profile: 
Active Pharmaceutical Ingredient: Prednisolone 
Therapeutic Class: Endocrine-metabolic agent, immune suppressant 
Therapeutic Indications: 
i. Skin: Pemphigus vulgaris, allergic dermatitis, eczema, exfolliative dermatitis, dermatitis herpetic 
formas, dermatitis medicamentosa, erythema multiforme, disseminated lupus erythematosus, 
dermatomyositis, polyarteritisnodosa. 
ii. Respiratory: Severe bronchial asthma and status asthmaticus, emphysema,pulmonary fibrosis. 
iii. Adrenal: Adrenal hyperplasia (adrenogenital syndrome). 
iv. Haematological: Idiopathic thrombocytopenic purpura, acquired haemolytic anaemia, 
acuteleukaemia. 
v. Other: Nephrotic syndrome, iridochoroiditis ulcerative colitis, rheumatoid arthritis, ankylosing 
spondylitis, rheumatic fever, gout, periarthritis of the shoulder.  
Description: Prednisolone is a synthetic glucocorticoid, a derivative of cortisol which is used to 
treat a variety of inflammatory and auto-immune conditions. It is the active metabolite of drug 
prednisone and it is used in patients with hepatic failure as they are unable to metabolize 
prednisone to prednisolone. 7 
Systemic (IUPAC) name: (8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-
hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-
one 
Molecular formula: C21H28O5 
Molecular Mass: 360.44402g/mol 
 
 
 
 
 
 
 
 
 
 
 
Structural formula: 
 
Appearance: White to white crystalline powder
Solubility: in water, 2.23X10+2mg/L at 25° C
Melting point:235°C 
 
1.7 Mechanism of action: 
Prednisolone can inhibit leukocyte infiltration at the site of 
mediators of inflammatory response, and suppress humoral immune responses. The ant
inflammatory actions of glucocorticoids are thought to involve phospholipase A
proteins, lipocortins, which control the biosynthesis
prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the 
capillary dilatation and permeability of the vascular structures. These compounds restrict the 
accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of 
vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of 
arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. 
Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor
complex translocate itself into the cell nucleus, where it binds to many glucocorticoid response 
elements (GRE) in the promoter region of the target genes. The DNA bound receptor t
interacts with basic transcription factors, causing an increase or decrease in expression of 
specific target genes, including suppression of IL2 (interleukin 2) expression.
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1.8 Pharmacodynamic properties:  
Prednisolone acts through replacing adrenal insufficiency as in Addison’s disease, or after 
adrenalectomy. Prednisolone has anti-inflammatory and immuno-suppressant glucocorticoid 
properties. 
 
1.9 Pharmacokinetic properties:  
Prednisolone is absorbed from the gastro-intestinal tract and peak plasma concentrations are 
obtained 1 to 2 hours after administration. The drug has a plasma half-life of 2-3 hours and is 
extensively bound to plasma protein. Prednisolone is excreted in the urine as free and conjugated 
metabolites, together with an appreciable amount of unchanged Prednisolone. Prednisolone 
crosses the placenta and small amounts are excreted in breast milk. The biological half-life of 
Prednisolone lasts for several hours.9 
 
1.10 Dosage and Administration: 
Route of administration: oral 
The lowest dose to produce an acceptable result should be given; when it is possible to reduce 
the dose this must be by stages. In prolonged treatment, the dose may be increased temporarily 
during periods of stress or exacerbation of illness. 
Adults:  
Short term treatment: 20 to 30mg daily for the first few days, reducing by 2.5 to 5mg every 2 to 5 
days according to the response.  
Rheumatoid arthritis: Initially 7.5 to 10mg daily reduced to the lowest effective dose for 
maintenance.  
Most other conditions: 10 to 100mg daily for 1 to 3 weeks, then reducing to the lowest effective 
dose.  
Elderly:  
There is no evidence that the dosage should differ; the dose should be the minimum necessary to 
achieve the desired therapeutic effect.  
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Children:  
At 12 years, 75% of the adult dose; at 7 years, 50% of the adult dose; at 1 year 25% of the adult 
dose dependent on clinical factors. Initial dose 0.75 to 1.0mg/kg of bodyweight daily, in divided 
doses.10 
Usual Adult Dose for Multiple Sclerosis: 
Tablets and syrup for acute exacerbations: 200 mg daily for one week followed by 80 mg every 
other day for 1 month. 
Usual Adult Dose for Bronchopulmonary Dysplasia: 
Tablets and syrup for acute exacerbations: 200 mg daily for one week followed by 80 mg every 
other day for 1 month. 
Usual Adult Dose for Anti-inflammatory: 
Sodium phosphate: 
Oral: 5 to 60 mg per day in divided doses 1 to 4 times/day. 
Intravenous or Intramuscular: 4 to 60 mg/day 
For intraarticular, intralesional or soft tissue administration: 
Large joints: 10 to 20 mg  
Small joints: 4 to 5 mg 
Bursae: 10 to 15 mg 
Tendon sheaths: 2 to 5 mg 
Soft tissue infiltration: 10 to 30 mg 
Ganglia: 5 to 10 mg 
Injectable suspension (tebutate) for intraarticular, intralesional or soft tissue administration: 
Large joints: 20 to 30 mg (doses > 40 mg not recommended) 
Small joints: 8 to 10 mg 
Bursae: 20 to 30 mg 
Tendon sheaths: 4 to 10 mg 
Ganglia: 10 to 20 mg 
Injectable suspension (acetate) for intraarticular, intralesional or soft tissue administration: 4 to 
100 mg 
Bursae: 10 to 15 mg 
 
 
9 
 
Tendon sheaths: 2 to 5 mg 
Soft tissue infiltration: 10 to 30 mg 
Usual Pediatric Dose for Immunosuppression: 
Oral: 0.1 to 2 mg/kg/day in divided doses 1 to 4 times a day. 
Intravenous: 0.1 to 2 mg/kg/day in divided doses 1 to 4 times a day. 
Usual Pediatric Dose for Asthma -- Acute: 
Oral: 1 to 2 mg/kg/day in divided doses 1 to 2 times a day for 3 to 5 days. 
Intravenous: 2 to 4 mg/kg/day divided 3 or 4 times a day. 
Usual Pediatric Dose for Nephrotic Syndrome: 
First 3 episodes: Initial dose: 2 mg/kg/day (maximum dose 80 mg/day) until urine is free of 
protein for 3 consecutive days (maximum: 28 days); followed by 1 to 1.5 mg/kg/dose every other 
day for 4 weeks. 
Frequent relapses or long-term maintenance dose: 0.5 to 1 mg/kg/dose given every other day for 
3 to 6 months. 
Usual Pediatric Dose for Bronchopulmonary Dysplasia: 
2 mg/kg/day orally divided twice daily for 5 days, followed by 1 mg/kg/day once daily for 3 
days, followed by 1 mg/kg/dose every other day for 3 doses.14 
 
1.11 Adverse Effects: 
Body as a whole: leucocytosis, hypersensitivity including anaphylaxis, thromboembolism, 
fatigue, malaise 
Cardiovascular: congestive heart failure in susceptible patients, hypertension 
Gastro-intestinal: dyspepsia, nausea, peptic ulceration with perforation and haemorrhage, 
abdominal distension, abdominal pain, increased appetite which may result in weight gain, 
diarrhoea, oesophageal ulceration, oesophageal candidiasis, acute pancreatitis 
Musculoskeletal: proximal myopathy, osteoporosis, vertebral and long bone fractures, avascular 
osteonecrosis, tendon rupture, myalgia 
Metabolic/Nutritional: sodium and water retention, hypokalaemic alkalosis, potassium loss, 
negative nitrogen and calcium balance 
Skin: impaired healing, hirsutism, skin atrophy, bruising, striae, telangiectasia, acne, increased 
sweating, may suppress reactions to skin tests, pruritis, rash, urticarial 
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Endocrine: suppression of the hypothalamo-pituitary adrenal axis particularly in times of stress 
as in trauma surgery or illness, growth suppression in infancy, childhood and adolescence, 
menstrual irregularity and amenorrhoea. Cushingoidfacies, weight gain, impaired carbohydrate 
tolerance with increased requirement for anti-diabetic therapy, manifestation of latent diabetes 
mellitus, increased appetite. 
Nervous system: euphoria, psychological dependence, depression, insomnia, dizziness, 
headache, vertigo, raised intracranial pressure with papilloedemain children, usually after 
treatment withdrawal. Aggravation of schizophrenia, Aggravation of epilepsy suicidal ideation, 
mania, delusions, hallucinations, irritability anxiety, insomnia and cognitive dysfunction. In 
adults the frequency of severe psychiatric reactions has been estimated to be 5-6%. 
Eye disorders: increased intra-ocular pressure, glaucoma, papilloedema, posteriorsubcapsular 
cataracts, exophthalmos, corneal or scleral thinning, exacerbation of ophthalmic viral or fungal 
disease 
Anti-inflammatory and Immunosuppressive effects: increased susceptibility to and severity of 
infections with suppression of clinical symptoms and signs. Opportunistic infections, recurrence 
of dormant tuberculosis. 
Withdrawal symptoms : Too rapid a reduction of prednisone following prolonged treatment 
can lead to acute adrenal insufficiency, hypotension and death. A steroid withdrawal syndrome 
seemingly unrelated to adrenocortical insufficiency may also occur and include symptoms such 
as anorexia, nausea, vomiting, lethargy, headache, fever, weight loss, and/or hypotension.  
 
1.12 Side Effects:  
Some common side effects of Prednisolone are mentioned below: 
fluid retention, weight gain, high blood pressure, potassium loss, headache, muscle weakness, 
puffiness of and hair growth on the face, thinning and easy bruising of the skin, glaucoma, 
cataracts, peptic ulceration, worsening of diabetes, irregular menses, growth retardation in 
children, convulsions, and psychic disturbances.  
 
 
 
 
 
 
11 
 
1.13 Contraindications 
Prednisolone is contraindicated in patients with: peptic ulcer, 
osteoporosis, psychosesor severe psychoneuroses. 
Prednisolone is usually contraindicated in the presence of acute infection 
Administration of live virus vaccines  
 
1.14 Use during Pregnancy  
The ability of corticosteroids to cross the placenta varies between individual drugs, however, 
88% of Prednisolone is inactivated as it crosses the placenta.  Administration of corticosteroids 
to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-
uterine growth retardation and effects on brain growth and development. There is no evidence 
that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft 
palate/ lip in man.  
However, when administered for prolonged periods or repeatedly during pregnancy, 
corticosteroids may increase the risk of intra-uterine growth retardation.  
Hypoadrenalism may, in theory occur in the neonate following prenatal exposure to 
corticosteroids but usually resolves spontaneously following birth and is rarely clinically 
important. As with all drugs, corticosteroids should only be prescribed when the benefits to the 
mother and child outweigh the risks. When corticosteroids are essential however, patients with 
normal pregnancies may be treated as though they were in the non-gravid state.10  
Lactation  
Corticosteroids are excreted in small amounts in breast milk. However doses of up to 40mg daily 
of prednisolone are unlikely to cause systemic effects in the infant. Infants of mothers taking 
higher doses than this may have a degree of adrenal suppression but the benefits of breast-
feeding are likely to outweigh any theoretical risk.10 
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1.15 Drug Interactions: 
Hepatic microsomal enzyme inducers: Medicines that induce hepatic enzyme cytochrome P-
450 isozyme 3A4 such as Phenobarbital, phenytoin, rifampicin, rifabutin, carbamazepine, 
primidoneandamino-gluethimide may reduce the therapeutic efficacy of corticosteroids by 
increasingthe rate of metabolism. 
Hepatic microsomal enzyme inhibitors: Medicines that inhibit hepatic enzyme cytochrome P-
450 isozyme 3A4 such asketoconazole, ciclosporin or ritonavir may decrease glucocortiocoid 
clearance. A reduction in prednisone dose may be needed to reduce the risk of adverse effects. 
Antidiabetic Agents: Prednisolone may increase blood glucose levels. Patients may need dosage 
adjustment of any concurrent anti-diabetic therapy. 
Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant administration may increase 
the risk of gastro-intestinal tract ulceration. Aspirin should be used cautiously in conjunction 
with prednisone in patients with hypo-thrombinaemia. The renal clearance of salicylates is 
increased by corticosteroids and steroid withdrawal may result in salicylate intoxication. Patients 
should be observed closely for adverse effects of either medicine. 
Anticoagulants: Response to anticoagulants may be reduced or less often enhanced by 
corticosteroids.  
Antifungals: The risk of hypokalaemia may be increased with amphoteracin. 
Cardiac glycosides: There is a risk of toxicity if hypokalaemia occurs due to prednisone 
treatment. 
Cytotoxic agents: There is an increased risk of haematological toxicity when prednisone is 
given with methotrexate. 
Mifepristone: The effect of corticosteroids may be reduced for 3-4 days after mifepristone. 
Vaccines: Live vaccines should not be given to individuals with impaired immune 
responsiveness. The antibody response to other vaccines may be diminished. 
Oestrogens: Oestrogens may potentiate the effects of glucocorticoids. The dose of prednisone 
may need to be adjusted if oestrogen therapy is commenced or stopped. 
Somatropin: The growth promoting effect may be inhibited. 
Sympathomimetics: There is an increased risk of hypokalaemia if high doses of corticosteroids 
are given with high doses of salbutamol, salmeterol, terbutaline or formoteral. 
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Diuretics: Excessive potassium loss may be experienced if glucocorticoids and potassium 
depleting diuretics (such as fursemide and thiazides) or carbonic anhydrase inhibitors (such as 
acetazolamide) are given together. 
Antacids: Concurrent use of antacids with prednisone may decrease absorption of these 
glucocorticoids efficacy may be decreased sufficiently to require dosage adjustments in patients 
receiving small doses of prednisone.  
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1.16 Available dosage forms of prednisolone in Bangladesh: 
Brand Name Dosage Dosage Form Manufacturer 
Cortan Prednisolone 5mg, 
10mg & 20mg 
Tablet Incepta Pharmaceuticals 
Ltd. 
Deltacort Prednisolone 5mg Film Coated Tablet Desh Pahrmaceuticals 
Ltd. 
Deltapred Prednisolone 5mg Film Coated Tablet Ziska Pharmaceuticals 
Ltd. 
Deltasone Prednisolone 5mg, 
10mg & 20mg  
Tablet Renata Ltd. 
G-prednisolone Prednisolone 5mg Film Coated Tablet  Gonoshasthya 
Pharmaceuticals Ltd. 
Precodil Prednisolone 5mg & 
20mg  
Tablet OpsoninPharma Limited 
Prednelan Prednisolone 20mg Tablet Glaxo Smith kline(BD) 
Ltd 
Prednicortil Prednisolone 5mg Tablet GacoPharmceuticals 
Ltd. 
Prednisolone Prednisolone 5mg Tablet Glaxo Smith kline(BD) 
Ltd 
Prexan Prednisolone 5mg Film Coated Tablet Chemist Laboratories 
Ltd. 
Redisone Prednisolone 5mg Film Coated Tablet Rephco Laboratories 
Ltd. 
Zenilon Prednisolone 5mg Film Coated Tablet Zenith Pharmaceuticals 
Ltd.  
 
 
Table 1.1: Table showing the available dosage forms of prednisolone in Bangladesh 
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Figure 1.1: Picture of Cortan® 5mg& 20mg prednisolone tablets manufactured and marketed by 
Incepta Pharmaceuticals Ltd. 
 
 
 
Figure 1.2: Picture of Inflagic® 5mg tablets manufactured and marketed by Square 
Pharmaceuticals Ltd. 
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2.1 Materials: 
Serial 
number 
Instrument Model/Manufacturer 
Country of 
origin 
1.  Slide caliper (0-150X0.05mm)  China 
2.  Electronic balance Shimadzu Japan 
3.  Friabilator (USP) Electrolab, EF-2 India 
4.  Disintegration Tester (USP) Electrolab, ED-2L India 
5.  Dissolution Tester 
Logan Instruments Corp., 
UDT-804 
USA 
6.  UV-Visible Spectrophotometer Hitachi Japan 
7.  
High Performance Liquid 
Chromatography (HPLC) 
Shimadzu Japan 
8.  Sonicator Shimadzu Bangladesh 
9.  pH meter Shimadzu Bangladesh 
10.  Lab stirrer Shimadzu Bangladesh 
11.  Water suction filtration Shimadzu Bangladesh 
 
Table2.1: List of instruments and Equipment used in the analysis 
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Serial 
Number 
Name Specification 
1.  Volumetric flask 10ml, 20ml, 50ml, 1000ml 
2.  Pipette(graduated & volumetric) 1ml, 2ml, 4ml, 5ml, 10ml 
3.  Beakers 
10ml, 25ml, 50ml, 100ml, 
500ml, 1000ml 
4.  Funnel Small, medium 
5.  Measuring cylinder 500ml, 1000ml 
6.  Pipette filler Bangladesh 
7.  Filter paper Whitman 
8.  Injection syringe with 0.45µ disk filter Bangladesh 
9.  Mortar & Pestle Small, medium 
 
Table2.2: List of apparatus and glass wares used in the experiment 
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Sample Number Batch No. Expiry date 
Sample 1 602-28-50 APR 16 
Sample 2 602-28-50 MAY 16 
Sample 3 13059 E0816 AUG 
Sample 4 13059 E0816 AUG 16 
Sample 5 B166 AUG 16 
Sample 6 B167 AUG 16 
Sample 7 336E0916 SEP 16 
Sample 8 346E0916 SEP 16 
Sample 9 408002 JULY 16 
Sample 10 408004 SEP 16 
Sample 11 B06E02 2017 FEB 17 
Sample 12 B10E02 2017 FEB 17 
 
Table 2.3: List of tablets from different samples and their batch number and expiry date 
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Pictures & Images of the Instruments: 
 
 
Figure 2.1: Picture showing slide caliper Figure 2.2: Picture showing an electronic balance 
 
Figure 2.3: Tablet friability tester  Figure 2.4: Picture showing disintegration tester 
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Figure 2.5: Picture showing UV-Visible spectrophotometer 
 
Figure 2.6: Picture showing dissolution tester 
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Figure 2.7: Picture showing the paddle of dissolution tester 
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Figure 2.8: Picture showing the HPLC machine 
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2.2 Assay of Prednisolone by High Performance Liquid Chromatography 
(HPLC)  
Principle: 
A prepared standard and sample solution are injected consequently into suitable column of High 
Performance Liquid Chromatography (HPLC). The content of Prednisolone present in each 
sample is calculated by comparing both the peak areas of active Prednisolone present in the 
standard preparation and prepared sample. 
 
Procedure: 
 
Chromatographic Conditions:  
 
Apparatus Specifications 
HPLC machine Shimadzu HPLC-prominence integrated with 
spectrophotometric UV detector 
Column 4.6mmX 30cm, C18 
Mobile phase, Mixture of Solution Water saturated butyl chloride, 
Tetrahydrofuran, Methanol and Glacial acetic 
acid (95:14:7:6). 
Flow rate 1.0µl 
Wavelength 254nm 
Load 10µl 
Temperature 40°C 
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Standard preparation: 
5mg of working standard of prednisolone was weighed and transferred into a clean and dry 25ml 
volumetric flask. Solution was made by adding diluting solution and was put in the sonicator for 
5 minutes to make homogenous solution. 5ml of the above solution was transferred into a clean 
and dry 50ml volumetric flask and diluted with diluting solution. The solution was mixed well in 
the sonicator to make a homogenous solution of 20µg/ml. the solution was injected to two vials 
through 0.45µ disk filter. These were called as standard solutions. 
 
Sample preparation: 
Approximately 5mg Prednisolone tablets were weighed and made fine powder by crushing with 
mortar and pestle. Then the fine powdered sample was transferred into a clean and dry 25ml 
volumetric flask. The 10ml of diluting solution was added and shaken well. The solution was 
then put in the sonicator for 5 minutes and the volume was adjusted to the mark with the diluting 
solution and mixed well. 5ml of the above solution was then transferred into a 50ml clean and 
dry volumetric flask. 20ml of diluting solution was added and shaken well. The solution was put 
in the sonicator for 5minutes and made up to the mark with diluting solution. The concentration 
of the sample is the 20µg/ml. the solution was mixed well and injected into four vials through 
0.45µ disk filter. These were called as sample solution. The above procedure was followed for 
twelve different companies and their tablets.  
 
Procedure: 
Two vials containing standard solution and four vials containing sample solution were placed 
into the tray of the auto sampler of Shimadzu HPLC machine. The instrument was started to run 
and the chromatography was recorded. 
 
Calculation:  
The quantity of Prednisolone was calculated in sample using the following equation: 
Prednisolone Content %: 
Peak area of sample solution  weight of standard (mg)   Potency of standard 
Peak Area of standard solution Weight of sample (mg) 
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2.3 In-vitro dissolution study 
Principle: 
 Release rate of Prednisolone tablet is carried on according to the general procedure of United 
States Pharmacopoeia (USP). Samples of dissolution fluid are withdrawn and analyzed by UV 
Spectrophotometer. The measurement is done at the wavelength at which the absorption is 
maximum. By comparing with absorbance of standard solution, the amount of active 
Prednisolone in tablets released is calculated.  
Conditions: 
Apparatus USP 2 Paddle 
Dissolution medium 900ml pH 7, Distilled water 
Temperature 37°C (±0.5) 
Stirring Speed 50rpm 
Time 30 minutes 
 
Preparation of Standard Solution: 
50mg of working standard of Prednisolone was weighed and transferred into a clean and dry 
100ml volumetric flask. Then 90ml of distilled water was added to the volumetric flask and 
shaken. The volumetric flask is put in the sonicator for 5 minutes and made up to the mark. From 
the above solution 10ml is taken in another clean and dry 100ml volumetric flask and 50ml 
distilled water is added to make the solution. The solution is put in sonicator for 5minutes and 
the volume is adjusted to make up the mark. Concentrations of 1mg.ml, 2mg/ml, 3mg/ml, 
4mg/ml and 5mg/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
Standard curve of Prednisolone:
Concentration(mg/ml)
 
Table 2.4: Standard curve of Prednisolone
 
Figure 2.3.1: Standard curve of Prednisolone
 
 
 
 
 
 Absorbance 
0 0 
1 0.07 
2 0.13 
3 0.19 
4 0.24 
5 0.326 
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Preparation of sample solution: 
900ml of distilled water was placed into each of six dissolution vessels and the temperature was 
set to 37°C(±0.5). Weighed tablets of Prednisolone were transferred to each six baskets. The 
baskets were immersed into the medium to a distance 25±2 mm between the basket and bottom 
of the vessel. The apparatus was started to operate at the specified rpm. At the end of 1st hour, 
10ml samples were withdrawn from each vessel and filtered through Whatman filter paper 
discarding first few ml of filtrate. The withdrawn quantity of samples was replaced by fresh 
dissolution medium to maintain constant volume of dissolution medium. 4ml of the filtrate were 
diluted with distilled water into 10ml volumetric flask and mixed well. 
Then the absorbance of the above solution in a 1cm silica cell were measured at the wavelength 
of maximum absorbance at 246nm by UV-visible spectrophotometer using distilled water as 
blank.  
The amount of drug present in the samples was calculated with the help of straight-line equation 
obtained from the calibration curve of Prednisolone. The dissolution study was continued for 1 
hour to get a simulated picture of the drug release in the in-vitro condition  
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2.4 Physical parameters of Prednisolone: 
 
Weight variation: A fundamental quality attribute for all pharmaceutical preparations is the 
requirement for a constant dose of drug between individual tablets. Small variations between 
individual preparations are accepted.11 The test for uniformity of weight is carried out by 
collecting sample of tablets, from a batch and determining their individual weight. The average 
weight of the tablets is then calculated. The sample complies with the standard if the individual 
weights do not deviate from the mean more than is permitted in terms of percentage. 
 
Thickness: The thickness of a tablet is the only dimensional variable related to the process. At a 
constant compressive load, tablet thickness varies with changes in the die fill, with particle size 
distribution and packing of particle mix, being compressed and with tablet weight while with a 
constant die fill, thickness varies with variations in compressive load. Tablet thickness is 
consistent batch to batch or within a batch only if the tablet granulation or powder blend is 
adequately consistent in particle size and size distribution, if the punch tooling is of consistent 
length, and if the tablet press is clean and in good working order. The thickness of individual 
tablets can be measure with slide calipers which permits accurate measurements and provides 
information on the variation between tablets.  Tablet thickness should be with in ±5% variation 
of standard value. 
 
Hardness: Tablets require a certain amount of strength or hardness and resistance to friability, to 
withstand mechanical shocks of handling in manufacture, packaging and shipping. Adequate 
tablet hardness and resistance to powdering and friability are necessary requisites for consumer 
and acceptance. Monitoring of tablet hardness is especially important for drug products that 
possess real or potential bioavailability problems or that are sensitive to altered dissolution 
release profiles as a function of the compressive force employed. 
 
Friability: The laboratory friability tester is known as Roche friabilator. This device subjects a 
number of tablets to the combined effects of abrasion and shock by utilizing aplastic chamber 
that revolves at 25rmp dropping the tablets a distance of six inches with each revolution. 
Normally a reweighed tablet sample is placed in the friabilator which is then operated for 
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100revolutions. The tablets are then dusted and reweighed. Conventional compressed tablets that 
lose less than 0.5 to 1.0% of their weight are generally considered acceptable.  
 
Disintegration: The first important step toward solution is breakdown of the tablet into smaller 
particles or granules a process known as disintegration. The time that it takes a tablet to 
disintegrate is measured in a device described in the USP. The USP device to test disintegration 
uses 6 glass tubes that are 3 inches long, open at the top and held against a 10 mesh screen at the 
bottom end of the basket rack assembly. To test for disintegration time, one tablet is placed in 
each tube and the basket rack is positioned in a 1 liter beaker of water, at 37 ± 2°C such that the 
tablets remain 2.5cm below the surface of the liquid on their upward movement and descend not 
closer than 2.5cm from the bottom of the beaker. A standard motor driven device is used to move 
the basket assembly containing the tablets up and down through a distance of 5 to 6 cm at a 
frequency of 28 to 32 cycles per minute. Perforated plastic discs may also be used in the test. 
These are placed on top of the tablets and impart an abrasive action to the tablets.  
 
2.5 Collection of sample 
The samples for this project where purchased from different retail pharmacies from the following 
areas: Mohakhali wireless gate, Banani road 11, Kallynpur bus stand and Gulshan. All the 
purchased samples were stored in the favorable conditions and away from direct sunlight. The 
samples were taken and verified before carrying out any type of experiment on them.  
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Chemical analysis: 
3.1 HPLC assay values of Prednisolone tablets of different samples - 
% Prednisolone content 
Tablet 
number 
Sample 
1 
(local) 
Sample 
2 
(local) 
Sample 
3 
(local) 
Sample 
4 
(local) 
Sample 
5 
(multi-
nationa
l) 
Sample 
6  
(Multi-
nationa
l) 
Sample 
7 
(local) 
Sample 
8 
(local) 
Sample 
9 
(local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 99.66 79.98 82.83 83.28 96.03 97.81 95.65 93.36 91.85 82.37 76.89 76.22 
2 97.62 77.93 81.52 80.52 97.78 97.43 97.38 99.92 91.75 82.32 76.87 75.76 
3 97.98 78.3 66.52 84.02 93.75 96.34 93.38 95.73 91.8 82.23 74.64 75.96 
4 96.74 77.05 60.64 83.34 93.57 95.72 93.20 95.37 91.75 82.16 73.88 75.72 
5 95.9 76.21 52.49 83.71 92.43 94.98 92.06 96.55 91.72 82.09 72.75 75.59 
6 95.06 75.37 44.33 84.08 91.29 94.25 90.93 97.74 91.7 82.02 71.63 75.46 
 
Table 3.1: Percentage of Prednisolone content of tablets of different samples 
33 
 
 
 
 
 
 
 
 
Figure 3.1: Bar chart showing percentage of Prednisolone content of tablets of different  
The results of HPLC analysis are presented in the bar chart above, from the above bar chart we 
can see that the percentage of Prednisolone content varies from one sample to another. The 
lowest percentage content of Prednisolone was found of sample 12was 75.21%. The highest 
percentage content of Prednisolone was found for sample 6 and that was 97.81%. According to 
USP monographs HPLC assay should be within 90%-110%, from the result above we observe 
six samples give HPLC assay more than 90% the rest of the six samples are below 90% HPLC 
assay. 
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Figure 3.1.1: HPLC report of Prednisolone standard 1 
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Figure3.1.2: HPLC report of Prednisolone standard 2 
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Figure3.1.3: HPLC report of Prednisolone sample 1 
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Figure3.1.4: HPLC report of Prednisolone sample 2 
 
 
 
 
 
Figure 3.1.5: HPLC report of Prednisolone sample 3 
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Figure 3.1.6: HPLC report of Prednisolone sample 4 
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Figure 3.1.7: HPLC report of Prednisolone sample 5 
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Figure 3.1.8: HPLC report of Prednisolone sample 6 
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3.2 In-vitro dissolution study results 
% Drug Released 
Sample 
Number 
Sample 
1 (local) 
Sample 
2 (local) 
Sample 
3 (local) 
Sample 
4 (local) 
Sample 
5(Multi-
national) 
Sample 
6 (Multi-
national) 
Sample 
7 (local) 
Sample 
8 (local) 
Sample 
9 (local) 
Sample 
10(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 79.40 61.78 12.20 11.45 70.74 78.56 94.14 76.58 76.34 56.58 46.75 48.25 
2 74.82 62.29 11.54 10.85 79.57 79.85 90.74 75.95 78.38 55.95 48.71 49.78 
3 72.46 60.08 10.86 12.47 72.46 72.35 92.10 76.75 74.82 56.75 49.57 48.62 
4 71.95 69.57 12.56 12.32 76.85 75.27 95.84 75.85 78.81 55.85 48.35 49.35 
5 78.67 60.76 11.65 10.75 71.65 72.85 92.65 72.59 78.65 52.59 47.65 48.25 
6 79.67 61.61 12.45 11.95 72.21 70.32 93.52 73.85 77.52 54.81 49.25 48.72 
7 70.65 60.25 10.98 10.85 75.85 71.20 92.85 75.25 70.95 55.25 48.45 49.65 
8 72.45 60.59 11.54 11.35 78.65 79.85 91.65 79.57 72.56 59.57 49.51 50.25 
 
Table 3.2: Table of in-vitro dissolution of Prednisolone tablets of different samples 
 
 
 
Figure 3.2: Bar chart of in-vitro dissolution of Prednisolone tablets 
According to USP not less than 75% of the labeled amount of Prednisolone should be dissolved 
in 30 minutes, whereas the results show only
undergoing dissolution in order to be absorbed in the
undergo dissolution no absorption will take place. Only six brands passed the dissolution test, 
samples of six brands where below 75%. 
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3.3 Physical analysis: 
All physical tests parameters for the tablets are done according to USP (United States 
Pharmacopeia) and BP(British Pharmacopeia). The parameters are shape, color, appearance and 
size. 
Sample number Shape 
Sample 1(local) Oval 
Sample 2(local) Arc triangle 
Sample 3(local) Arc triangle 
Sample 4(local) Round 
Sample 5(multi-national) Round 
Sample 6 (multi-national) Round 
Sample 7(local) Round 
Sample 8(local) Oval 
Sample 9 (local) Oval 
Sample 10( local) Oval 
Sample 11( local) Oval 
Sample 12 (local) Oval 
 
Table 3.3: Table showing shapes of different company tablets 
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3.4 Weight Variation: 
Weight (gm) 
Tablet 
number 
Sample 
1(local) 
Sample 
2 (local) 
Sample 
3 (local) 
Sample 
4  
( local) 
Sample 5 
(multi-
national) 
Sample 6 
( Multi-
national) 
Sample 
7 (local) 
Sample 
8 (local) 
Sample 
9 (local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 0.138 0.131 0.18 0.18 0.101 0.098 0.066 0.066 0.151 0.154 0.151 0.148 
2 0.133 0.142 0.173 0.177 0.100 0.100 0.066 0.065 0.147 0.151 0.152 0.155 
3 0.134 0.134 0.181 0.179 0.100 0.098 0.067 0.066 0.156 0.154 0.146 0.158 
4 0.136 0.131 0.179 0.176 0.100 0.100 0.065 0.067 0.148 0.151 0.144 0.154 
5 0.134 0.138 0.175 0.179 0.098 0.101 0.065 0.065 0.153 0.153 0.153 0.152 
6 0.138 0.134 0.179 0.175 0.100 0.098 0.065 0.063 0.152 0.152 0.157 0.149 
7 0.131 0.136 0.176 0.179 0.102 0.100 0.065 0.065 0.151 0.153 0.154 0.152 
8 0.142 0.134 0.179 0.181 0.100 0.100 0.065 0.068 0.154 0.148 0.154 0.153 
9 0.134 0.138 0.177 0.173 0.098 0.098 0.063 0.067 0.154 0.147 0.152 0.157 
10 0.131 0.135 0.180 0.180 0.100 0.097 0.066 0.064 0.151 0.152 0.154 0.158 
 
 
Table 3.4: Table showing weight variation of ten tablets from different samples 
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Figure 3.3: Bar chart showing weight variation of different samples 
From the bar chart of weight variation it can be concluded that all the tablets are of uniform 
weight. The average weight of all tablets of each sample is in the same range. 
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3.5 Thickness: 
 
Thickness( cm) 
Tablet 
number 
Sample 
1(local) 
Sample 
2 (local) 
Sample 
3 
(local) 
Sample 
4 ( 
local) 
Sample 5 
(Multi-
national) 
Sample 6 
(Multi-
national) 
Sample 
7 
(local) 
Sample 
8 
(local) 
Sample 
9 
(local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.31 0.31 0.33 0.31 
2 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.31 0.32 0.32 0.33 
3 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.31 0.31 0.31 0.32 
4 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.32 0.32 0.33 0.31 
5 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.33 0.3 0.32 0.32 
6 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.31 0.3 0.3 0.33 
7 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.33 0.34 0.32 0.31 
8 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.32 0.32 0.33 0.32 
9 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.31 0.32 0.32 0.33 
10 0.3 0.3 0.35 0.35 0.2 0.2 0.2 0.2 0.33 0.31 0.33 0.3 
 
Table 3.5: Table showing thickness variability of different samples 
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Figure3.4: Bar chart showing thickness variability of different samples 
All the tablets of different companies have a uniform thickness. There is no major variability 
in their thickness. There is only variation from one sample to another 
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3.6 Hardness: 
Hardness(kg) 
Tablet 
number 
Sample 
1(local) 
Sample 
2 (local) 
Sample 
3 (local) 
Sample 
4 ( 
local) 
Sample 5 
(multi-
national) 
Sample 6 
(Multi-
national) 
Sample 
7 (local) 
Sample 
8 (local) 
Sample 
9 (local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 2.68 2.92 8.25 9.21 5.62 5.65 4.65 4.73 2.75 2.78 3.65 3.27 
2 3.48 2.24 10.47 12.56 5.18 5.43 4.81 4.15 2.98 2.54 3.74 3.45 
3 2.63 2.84 10.55 11.65 6.06 5.34 3.8 4.69 2.56 2.89 3.42 3.86 
4 2.02 3.67 12.25 10.85 5.38 4.17 3.84 4.28 2.78 2.84 3.21 3.92 
5 3.72 2.48 9.10 10.31 5.86 4.72 4.73 4.95 2.68 2.57 3.52 3.84 
6 2.26 2.95 8.77 9.45 5.42 4.38 4.16 4.75 2.49 2.82 3.58 3.73 
7 2.67 2.98 10.11 9.87 4.81 4.24 4.77 4.64 2.65 2.92 4.57 3.41 
8 2.39 2.52 10.55 10.75 4.41 5.81 3.96 3.97 2.58 2.71 3.81 3.25 
9 4.21 2.54 8.21 11.85 4.85 5.63 3.15 4.27 2.48 2.82 3.72 4.85 
10 2.55 3.24 9.1 12.34 5.54 4.97 4.37 4.87 2.29 2.45 3.14 3.24 
 
Table 3.6: Table showing hardness variability of different samples 
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Figure 3.5 Hardness variability of ten tablets of different samples 
Hardness of each tablet of each company varies with tablets, but they are in the same range. 
Only two samples show very high hardness around the range of 10-12 kg. 
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3.7 Friability: 
Total weight of 10 tablets (gm) 
 
Sample 
1(local) 
Sample 
2 (local) 
Sample 
3 (local) 
Sample 
4 (local) 
Sample 5 
(Multi-
national) 
Sample 6 
(Multi-
national) 
Sample 
7 (local) 
Sample 
8 (local) 
Sample 
9 (local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
before 1.352 1.452 1.785 1.654 0.99 1.102 0.654 0.665 1.513 1.515 1.518 1.52 
after 1.351 1.452 1.785 1.654 0.99 1.102 0.653 0.665 1.512 1.515 1.518 1.52 
 
Table 3.7: Friability test of different samples and their total weight before and after the test 
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Figure 3.6: Bar chart of friability test of different samples and their total weight before and 
after the test 
Total weight of 10 tablets before and after the friability test is found the same. There was no 
significant loss in weight of the tablets after the test for all the samples. 
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3.8 Disintegration time: 
Disintegration time (minutes) 
Tablet 
number 
Sample 
1(local) 
Sample 
2 (local) 
Sample 3 
(local) 
Sample 4  
( local) 
Sample 5 
(multi-
national) 
Sample 6 
( Multi-
national) 
Sample 
7 
(local) 
Sample 
8 
(local) 
Sample 
9 
(local) 
Sample 
10 
(local) 
Sample 
11 
(local) 
Sample 
12 
(local) 
1 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
2 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
3 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
4 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
5 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
6 8 7 
Did not 
disintegrate 
Did not 
disintegrate 
2 2 3 3 6 6 8 8 
 
Table 3.8: Table showing the disintegration time of different samples 
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Figure 3.7: Bar chart showing the different disintegration time of different samples 
 
Disintegration could be related to dissolution and similarly availability of drug to body 
(absorption) and finally the therapeutic efficacy of product. The result showed that 
disintegration time of all the selected tablets was found to be within specified limits of USP 
and BP. According to USP, uncoated tablets have disintegration time standards as low as 5 
minutes. For sample 3 and 4 it is seen no disintegration takes place. Which shows the drug 
does not undergo dissolution and is substandard.  
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4. Conclusion 
 
Although a wide range of synthetic glucocorticoids are now available, prednisolone still 
remains the most popular choice in glucocorticoid therapy, especially for oral 
administration.15  
Falsified and substandard drugs may contain toxic ingredients; some of the most compelling 
stories of pharmaceutical crime are of frank poisoning. By far the more common problem 
however, is medicine that simply does not work. Poor quality medicines cause treatment 
failure, but doctors do not generally suspect medicines as a cause of disease progression. 
Lifesaving medicines can be of poor quality, which may be an uncounted root cause of high 
mortality in low- and middle-income countries. No class of drug is immune to being 
compromised. Medications for chronic and infectious diseases alike have been found falsified 
and substandard. A considerable body of research indicates that inexpensive antimicrobial 
drugs in low- and middle-income countries are frequently poor quality. This not only put 
patients at risk, but encourages drug resistance, thereby threatening population health for 
future generations. Falsified and substandard drugs increase costs to patients and health 
systems. Medicines are expensive; patients and governments waste money on ineffective 
ones. Lingering illnesses decrease productivity, causing workers to forgo pay and spend more 
on treatment. Through encouraging antimicrobial resistance, illegitimate medicines reduce 
the effective life of a drug. Society must bear the cost of drug development, an expense that 
increases as drugs become more complex. 
Close monitoring of different process in pharmaceutical industries will reduce the production 
time and cost, as well as will improve the quality of the product. It was found that dissolution 
was the critical parameter where problem exist among different brands. Only six brands 
passed the dissolution test, tablets of six brands where below 50% as well as in HPLC assay 
shows some of the companies are below90%. Two samples did not undergo disintegration at 
all that shows that the tablets are substandard. However, no major problem was found in 
tablet variation, thickness, friability and hardness. From the experiment we can conclude that 
50% of the companies in the urban area are substandard, whereas 50% companies provide 
standard drugs. It was noted that some of the local companies has very low price as compared 
to the multi-national companies having the same good quality but some local companies has 
nearly the same price as that of multi-national with low price.  
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The drug administration should make new policy and drug acts to stop adulteration and 
control substandard drugs. Extend their regulatory mandate to cover manufacturers of 
marketed pharmaceutical product particularly with regard to inspection of GMP compliance, 
and impose rigorous requirements for labeling and certificates of analysis for consignments 
moving in international commerce. Introduce regulations that require APIs and all other 
starting materials intended for the formulation of medicinal products to be clearly labeled 
“for pharmaceutical use” or with a suitable pictogram. Establish within the regulatory 
authority a multidisciplinary group to investigate illicit activities promptly and professionally. 
Monitor free ports and strengthen collaboration with law enforcement agencies including 
customs officials, and offices of criminal investigation, at national and international level. 
Seek to enact legislation that permits sequestration of assets gained by unlawful activity and 
seizure and destruction of products involved. 
In conclusion it can be said that the different brands of well reputed local pharmaceutical 
companies can be compared with that of multi-national companies. As in Bangladesh not 
only in rural areas but also in urban areas more medicine is required of high standard as more 
patients require better healthcare. However, products of some less known local 
pharmaceutical industry needs improvements in quality and should be strictly monitored for 
manufacturing of substandard dosage forms.  
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